

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Material Table of Contents

Supplemental Table 1. Description of the Kidney Replacement Therapy modality used

Supplemental Table 2. Circuit characteristics by treatment modality

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Table 1. Description of the Kidney Replacement Therapy modality used

	SCUF	PIRRT	CVVH
Centers	All	CCHMC	COA, SCH
Dose	NA	2000 mL/1.73m ² /hour	2000 mL/1.73m ² /hour or 24 mL/kg/hour
Duration	Continuous or Intermittent for 6-8 hours	6-8 hours	Continuous
Blood Flow	30-40 mL/min	30-40 mL/min	30-40 mL/min

SCUF, Slow Continuous Ultrafiltration; PIRRT, Prolonged Intermittent Renal Replacement Therapy; CVVH, Continuous VenoVenous Hemofiltration; CCHMC, Cincinnati Children’s Hospital Medical Center; COA, Children’s of Alabama; SCH, Seattle Children’s Hospital

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

Supplemental Table 2. Circuit characteristics by treatment modality

	SCUF N=157	PIRRT N=190	CVVH N=537
Blood flow rate (mL/minute)	40 (40, 40)	40 (40, 40)	35 (30, 40)
Cardiorespiratory support at initiation (or with complications at initiation)	1 (2)	7 (4)	20 (4)
Type of support needed* <ul style="list-style-type: none"> • Normal saline • Inotrope • Calcium Chloride • Albumin • Sodium bicarbonate • Blood Transfusion 	1	0 5 4	5 3 3 8 2 1
Circuits with complications during therapy	31 (20)	32 (17)	70 (13)
Type of complication* <ul style="list-style-type: none"> • Hypothermia • Bleeding • Hypotension • Clot • Thrombocytopenia • Seizure • Catheter malfunction • Other 	1 0 10 12 2 2 4 1	2 1 14 11 - - 4 8	1 16 13 29 - - 4 2
Anticoagulation <ul style="list-style-type: none"> • Heparin 			

Supplemental material is neither peer-reviewed nor thoroughly edited by CJASN. The authors alone are responsible for the accuracy and presentation of the material.

<ul style="list-style-type: none"> • Citrate • Argatroban • None • Unknown/Other 	93	140	498
	-	2	-
	10	-	4
	45	47	34
	9	1	1
Circuit life (hours)	4.5 (3.5, 6)	7 (6, 8)	66.4 (30.1, 71.7)
Circuit survival to 60 hours for continuous**	NA	NA	309/456 (68)
Circuit survival to 6 hours for intermittent	NA	168/180 (93)	NA

Continuous variables are shown as median (Interquartile range) and categorical data as number (%)

* Some patients needed more than 1 intervention or had multiple complications

** After censoring circuits that were changed due to patient issues or scheduling concerns

SCUF, Slow Continuous Ultrafiltration; PIRRT, Prolonged Intermittent Renal Replacement Therapy; CVVH, Continuous VenoVenous Hemofiltration